Deichman G, Dyakova N, Kashkina L, Matveeva V, Uvarova E
Laboratory of Antitumor Immunity, Institute of Carcinogenesis, N.N. Blokchin Cancer Research Center, Russian Academy of Medical Sciences, Kashirskoye shosse 24, 115478, Moscow, Russia.
Immunol Lett. 2001 Jan 15;75(3):209-14. doi: 10.1016/s0165-2478(00)00304-7.
As shown earlier, the cells transformed in vitro by various oncogenes, during subsequent in vivo growth were gradually replaced by descendant tumor cells, which co-expressed highly increased H(2)O(2)-catabolizing antioxidant activity (H(2)O(2)(CA)), and the ability to release PGE(2) (PGE(S)) in contact with natural killer cells; v-src was the only oncogene, which in vitro induced cells transformation characterised with the expression of [H(2)O(2)(CA)+PGE(S)] phenotype. Expression of [H(2)O(2)(CA)+PGE(S)] phenotype was providing tumor cells with significantly increased resistance to cytotoxic activities of macrophages and NK cells. However, the possible involvement of [H(2)O(2)(CA)+PGE(S)] phenotype in primary carcinogenesis remained obscure. Here, using three models of the primary virus-induced Syrian hamster tumors we demonstrated that Rous Sarcoma Virus-induced tumors arising after short latent period expressed [H(2)O(2)(CA) + PGE(S)] phenotype at appearance. During the latent periods of SV40- and SA7(C8)-induced tumors the cells expressing [H(2)O(2)(CA)+PGE(S)] phenotype gradually replaced the original [H(2)O(2)(CA)+PGE(S)]-phenotype-negative cell populations. The effectiveness of such selection correlated with the duration of in vivo tumor development. Thus it was shown, that selection of tumor cells expressing [H(2)O(2)(CA)+PGE(S)] phenotype is beginning and may be completed during the latent period of primary carcinogenesis. Taken together, data of this and preceding our studies on [H(2)O(2)(CA)+PGE(S)] phenotype demonstrate that in vivo the host innate immunity antitumor reactions are apparently responsible for the selection of rare tumor cell variants capable to defend themselves against CTA of Mph and NK.
如前所示,在体外被各种癌基因转化的细胞,在随后的体内生长过程中逐渐被后代肿瘤细胞取代,这些后代肿瘤细胞共同表达高度增加的H(2)O(2)分解抗氧化活性(H(2)O(2)(CA)),以及在与自然杀伤细胞接触时释放PGE(2)(PGE(S))的能力;v-src是唯一在体外诱导细胞转化并具有[H(2)O(2)(CA)+PGE(S)]表型表达特征的癌基因。[H(2)O(2)(CA)+PGE(S)]表型的表达使肿瘤细胞对巨噬细胞和NK细胞的细胞毒性活性具有显著增强的抗性。然而,[H(2)O(2)(CA)+PGE(S)]表型在原发性致癌过程中的可能作用仍不清楚。在这里,我们使用三种原发性病毒诱导的叙利亚仓鼠肿瘤模型证明,潜伏期短的劳氏肉瘤病毒诱导的肿瘤在出现时表达[H(2)O(2)(CA)+PGE(S)]表型。在SV40和SA7(C8)诱导的肿瘤潜伏期内,表达[H(2)O(2)(CA)+PGE(S)]表型的细胞逐渐取代了原来的[H(2)O(2)(CA)+PGE(S)]表型阴性细胞群体。这种选择的有效性与体内肿瘤发展的持续时间相关。因此表明,表达[H(2)O(2)(CA)+PGE(S)]表型的肿瘤细胞的选择在原发性致癌的潜伏期开始并可能完成。综上所述,本研究及之前我们关于[H(2)O(2)(CA)+PGE(S)]表型的研究数据表明,在体内宿主先天免疫抗肿瘤反应显然负责选择能够抵御巨噬细胞和NK细胞细胞毒性作用的罕见肿瘤细胞变体。